series-c-plus
Stage
2018
Founded
2
Investors
About
Travere Therapeutics is a biopharmaceutical company that develops and commercializes therapies for rare kidney diseases including Focal Segmental Glomerulosclerosis (FSGS), IgA Nephropathy (IgAN), Classical Homocystinuria (HCU), and Cystinuria.
Explore Travere Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.